{
  "catalysts": [
    {
      "ticker": "IMNM",
      "market_cap": "$1.95B",
      "conviction_score": 9,
      "thesis": "High-conviction Insider Aggression. CEO Clay Siegall (founder of Seagen) purchased ~$100k in open market shares at 52-week highs, signaling anticipation of a breakout or major fundamental development. Despite the bullish filing, price action was muted (-1.9%), creating a divergence between insider sentiment and market reaction.",
      "catalyst_details": "Form 4 filing on Dec 30/31, 2025, revealing CEO Clay Siegall bought 4,729 shares at $21.15. This follows a $400M financing, extending cash runway to 2028.",
      "earnings_date": "2026-03-19",
      "relative_volume": "Normal (1.0x 30d avg)",
      "stop_loss_trigger": "Close below $19.50 (Recent breakout support)",
      "sentiment": "Bullish",
      "prediction_market": "None available",
      "recency_proof": "https://www.investing.com/news/company-news/immunome-imnm-ceo-siegall-buys-100k-in-shares-93CH-3806442 (Timestamp: 2025-12-31)",
      "risk": "Clinical data failure (pipeline risk typical of biotech), though CEO buying mitigates.",
      "expected_upside": "15-20% drift to ~$25.00 on filings digestion",
      "mispricing_evidence": "Stock closed down -1.94% on the day the Form 4 was filed, failing to price in the CEO's aggression.",
      "x_sentiment": "Low buzz, largely unnoticed retail discussion."
    }
  ]
}